Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Though it isn't the easiest support channel to locate, the Hims chat support at least connects you to knowledgeable representatives who can personalize assistance to your specific needs
The Strategy: Pairing the medication with a strict Protein-First Diet Plan and a Resistance Training schedule
Additionally, documenting these changes thoroughly can be vital if you decide to pursue legal action
Henderson T, Shepheard J, Sundararajan V
Check GLP-1 dosing
Mechanism of Action Semaglutide: Single GLP-1 Agonist Semaglutide activates only the GLP-1 receptor: GLP-1 Receptor Effects: Stimulates insulin secretion (glucose-dependent) Suppresses glucagon release Slows gastric emptying Reduces appetite via hypothalamic signaling Promotes satiety Tirzepatide: Dual GLP-1/GIP Agonist Tirzepatide activates both GLP-1 and GIP receptors: GLP-1 Receptor Effects: Same as semaglutide (above) GIP Receptor Effects (Additional): Enhanced insulin secretion Direct adipose tissue effects Potential cardioprotective benefits May improve tolerability Complements GLP-1 signaling Why Dual Agonism Matters Semaglutide: GLP-1 Appetite + Glucose Tirzepatide: GLP-1 Appetite + Glucose + GIP Enhanced effects + Better tolerance The dual mechanism may explain tirzepatide's: Greater overall efficacy Potentially better GI tolerability Enhanced metabolic effects Efficacy Comparison Weight Loss Results Semaglutide Clinical Trials STEP 1 (Non-diabetic obesity): 2.4mg dose: 14.9% weight loss Placebo: 2.4% weight loss Duration: 68 weeks STEP 2 (Type 2 diabetes + obesity): 2.4mg dose: 9.6% weight loss Duration: 68 weeks Tirzepatide Clinical Trials SURMOUNT-1 (Non-diabetic obesity): 15mg dose: 20.9% weight loss 10mg dose: 19.5% weight loss Placebo: 3.1% weight loss Duration: 72 weeks SURMOUNT-2 (Type 2 diabetes + obesity): 15mg dose: 15.7% weight loss Duration: 72 weeks Direct Comparison Glycemic Control Side Effects Gastrointestinal Effects GI side effects are the most common with both medications: Key Finding: Tirzepatide shows lower rates of GI side effects despite greater efficacy
